DSpace university logo mark
Advanced Search
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > School of Medicine > Articles in academic journal >

Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: A multicenter trial in Japan.


File Description SizeFormat
JouInf_Izumikawa.pdf622.88 kBAdobe PDFView/Open

Title: Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: A multicenter trial in Japan.
Authors: Kohno, Shigeru / Izumikawa, Koichi / Ogawa, Kenji / Kurashima, Atsuyuki / Okimoto, Niro / Amitani, Ryoichi / Kakeya, Hiroshi / Niki, Yoshihito / Miyazaki, Yoshitsugu
Issue Date: Nov-2010
Citation: The Journal of infection, 61(5), pp.410-418; 2010
Abstract: Chronic pulmonary aspergillosis (CPA) is slowly progressive inflammatory pulmonary syndrome due to Aspergillus spp. The evidence regarding CPA treatment is limited. We conducted a randomized, multicenter, open-label trial comparing intravenous micafungin (MCFG) of 150-300 mg once daily with intravenous voriconazole (VRCZ) of 6 mg/kg twice on Day 1 followed by 4 mg/kg twice daily for the treatment of 107 in patients with CPA to compare the efficacy and safety of both drugs as initial treatment in Japan. Treatment effectiveness was defined by clinical, mycological, radiological and serological responses 2 weeks after the initial administration and at the end of therapy. The total of 50 and 47 patients were assigned to the MCFG and VRCZ groups, respectively. The difference in efficacy rates between MCFG and VRCZ was not significant, either after 2 weeks [68.0% vs. 58.7%; the absolute difference, 9.3% with a 95% confidence interval (CI), -9.97 to 28.58, P = 0.344] or at the end of therapy (60.0% vs. 53.2%; the absolute difference, 6.8% with a 95% CI, -12.92 to 26.54, P = 0.499). In the safety evaluation, fewer adverse events occurred in the MCFG than VRCZ group (26.4% vs. 61.1%, P = 0.0004). MCFG was as effective as VRCZ and significantly safer than as an initial treatment of CPA. (UMIN Clinical Trials Registry number, UMIN000001786.).
Keywords: Chronic pulmonary aspergillosis / Micafungin / Voriconazole
URI: http://hdl.handle.net/10069/24110
ISSN: 01634453
DOI: 10.1016/j.jinf.2010.08.005
PubMed ID: 20797407
Rights: Copyright © 2010 The British Infection Society Published by Elsevier Ltd.
Type: Journal Article
Text Version: author
Appears in Collections:Articles in academic journal

Citable URI : http://hdl.handle.net/10069/24110

All items in NAOSITE are protected by copyright, with all rights reserved.

 

Valid XHTML 1.0! Copyright © 2006-2015 Nagasaki University Library - Feedback Powerd by DSpace